1. Home
  2. ITRM vs NTIP Comparison

ITRM vs NTIP Comparison

Compare ITRM & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITRM
  • NTIP
  • Stock Information
  • Founded
  • ITRM 2015
  • NTIP 1990
  • Country
  • ITRM Ireland
  • NTIP United States
  • Employees
  • ITRM N/A
  • NTIP N/A
  • Industry
  • ITRM Biotechnology: Pharmaceutical Preparations
  • NTIP Multi-Sector Companies
  • Sector
  • ITRM Health Care
  • NTIP Miscellaneous
  • Exchange
  • ITRM Nasdaq
  • NTIP Nasdaq
  • Market Cap
  • ITRM 40.0M
  • NTIP 28.6M
  • IPO Year
  • ITRM 2018
  • NTIP 1998
  • Fundamental
  • Price
  • ITRM $1.16
  • NTIP $1.34
  • Analyst Decision
  • ITRM Strong Buy
  • NTIP
  • Analyst Count
  • ITRM 2
  • NTIP 0
  • Target Price
  • ITRM $7.00
  • NTIP N/A
  • AVG Volume (30 Days)
  • ITRM 612.5K
  • NTIP 25.7K
  • Earning Date
  • ITRM 08-13-2025
  • NTIP 08-11-2025
  • Dividend Yield
  • ITRM N/A
  • NTIP 7.62%
  • EPS Growth
  • ITRM N/A
  • NTIP N/A
  • EPS
  • ITRM N/A
  • NTIP N/A
  • Revenue
  • ITRM N/A
  • NTIP $250,000.00
  • Revenue This Year
  • ITRM N/A
  • NTIP N/A
  • Revenue Next Year
  • ITRM $270.19
  • NTIP N/A
  • P/E Ratio
  • ITRM N/A
  • NTIP N/A
  • Revenue Growth
  • ITRM N/A
  • NTIP N/A
  • 52 Week Low
  • ITRM $0.81
  • NTIP $1.16
  • 52 Week High
  • ITRM $3.02
  • NTIP $1.78
  • Technical
  • Relative Strength Index (RSI)
  • ITRM 61.00
  • NTIP 62.14
  • Support Level
  • ITRM $0.91
  • NTIP $1.20
  • Resistance Level
  • ITRM $1.03
  • NTIP $1.30
  • Average True Range (ATR)
  • ITRM 0.05
  • NTIP 0.06
  • MACD
  • ITRM 0.01
  • NTIP 0.01
  • Stochastic Oscillator
  • ITRM 95.18
  • NTIP 69.23

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

About NTIP Network-1 Technologies Inc.

Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.

Share on Social Networks: